The appeals court ruling blocks Sandoz from producing a biosimilar of Enbrel (etanercept) until 2029, more than thirty years after it was first approved. Sandoz, which is the biosimilars and ...

According to the complaint, Amgen and its affiliates “have for many years infringed the Iowa Patents with full knowledge of them” to produce Enbrel (etanercept) and Vectibix (panitumumab).